• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Kaletra (lopinavir and ritonavir) Solution for Oral Use October 2008

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2008


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View


Sections Modified


  • Established and Other Potentially Significant Drug Interactions
    • Table 9: Established and Other Potentially Significant Drug Interactions
      • Non-nucleoside Reverse Transcriptase Inhibitors
        • Efavirenz
      • HIV CCR5 – antagonist
        • Maraviroc
      • Anticancer Agents
        • Vincristine
        • Vinblastine
      • Anticonvulsants
        • Phenytoin
      • Antidepressant
        • Bupropion
      • Antifungals
        • Voriconazole